Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments

Chimeric antigen receptor (CAR) T-cell therapy exhibits desirable and robust efficacy in patients with acute lymphoblastic leukemia (ALL). Stimulated by the revolutionized progress in the use of FDA-approved CD19 CAR T cells, novel agents with CAR designs and targets are being produced in pursuit of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xinjie, Huang, Shengkang, Xiao, Xinyi, Sun, Qihang, Liang, Xiaoqian, Chen, Sifei, Zhao, Zijing, Huo, Zhaochang, Tu, Sanfang, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902522/
https://www.ncbi.nlm.nih.gov/pubmed/33643279
http://dx.doi.org/10.3389/fimmu.2020.569117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902522/
https://www.ncbi.nlm.nih.gov/pubmed/33643279
http://dx.doi.org/10.3389/fimmu.2020.569117

Ejemplares similares